Uri Ladabaum, MD
Gastroenterology · Stanford, CANPI 1245288059
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $15,000 of the $24,149 with a category attached, or 62.1%. Covidien LP accounts for 62.1% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2020 at $15,122 and has fallen 98.5% since, to $226 in 2025.
Across 10 payments — averaging $2414.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Covidien LP$15K
- Neptune Medical Inc.$6K
- Medtronic$3K
- Fujifilm Healthcare Americas Corporation$179
- Takeda Pharmaceuticals U.S.A., Inc.$122
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$47
What the payments were for
- Consulting fees$8,62536%
- Speaking & faculty fees$15,00062%
- Food & beverage$5242%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Covidien LP | 1 | $15,000 |
| Neptune Medical Inc. | 2 | $6,250 |
| Medtronic | 4 | $2,551 |
| Fujifilm Healthcare Americas Corporation | 1 | $179 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $122 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $47 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,149 in reported general payments places this provider in the 85th percentile of 1,885 gastroenterology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 12 | $14,502 |
| Esomeprazole Magnesium | 17 | $1,912 |
| Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg | 86 | $1,791 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 14 | $965 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 23 | $353 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 13 | $178 |
| Omeprazole | 13 | $145 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Stanford
- Joo HwangStanford$1M
- Shai FriedlandStanford$452K
- Mike WeiStanford$382K
- Margaret ZhouStanford$288K
- Andrew LiStanford$217K
- Walter ParkStanford$216K
- Paul KwoStanford$150K
- Bennett RothLos Angeles$2.8M
- Douglas NguyenMission Viejo$2M
- Sammy SaabLos Angeles$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.